Dr. John Gartner

John Gartner, MD CM, FRCPC
Professor, Department of Pathology

Professor, Department of Immunology
Professor, Department of Pediatrics & Child Health
Max Rady College of Medicine,
Rady Faculty of Health Sciences
University of Manitoba

1980 FRCPC, 1976 MD, CM


Office & Mail: 401 Brodie Centre, 727 McDermot Avenue, Winnipeg, MB, Canada R3E 3P5
T: 204 789-3382 | Lab: 204 789-3317| F: 204 789-3931
Research Interests:Dr. Gartner's laboratory investigates the immunological and pathological mechanisms underlying the development of graft versus host disease with particular focus on the intestinal complications of the disease, as well as the cells and cytokines involved in the development of lesions in the intestinal epithelium. Dr. Gartner, Dr. Cynthia Ellison and Dr. Kent HayGlass have studied the effects of exogenous KGF in mouse models of GVHD with emphasis on its immunomodulatory properties and therapeutic potential. They found that KGF protects against the morbidity of acute GVHD by preventing the development of intestinal epithelial cell apoptosis and by shifting the immune response from a destructive Th1-mediated cytokine response to a mixed Th1/Th2 cytokine profile.  These protective effects are only present when KGF works in concert with thymic stromal lymphopoietin (TSLP), an immunomodulatory cytokine that is produced primarily by epithelial cells. This work has led to a new hypothesis that TSLP modulates immune responses to breast cancer, a new area under investigation in the laboratory. Studies are also underway to investigate how tight junctions and claudin expression is modulated during the evolution of acute and chronic GVHD and how this influences the development of endotoxemia, a major feature of acute GVHD that plays a key role in the immunopathogenesis of the disease and is fatal if untreated.